埃克替尼-话题@MedSci

#埃克替尼#

17篇内容 | 912人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2174227, encodeId=263021e422787, content=<a href='/topic/show?id=32af9938ec6' target=_blank style='color:#2F92EE;'>#非小细胞肺癌#</a> <a href='/topic/show?id=4c496569c8' target=_blank style='color:#2F92EE;'>#EGFR#</a> <a href='/topic/show?id=011941548ad' target=_blank style='color:#2F92EE;'>#埃克替尼#</a> <a href='/topic/show?id=c0501084e91d' target=_blank style='color:#2F92EE;'>#贝福替尼#</a>, objectTitle=贝家讲坛 | 聚焦脑转移与共突变人群，原研EGFR-TKI贝福替尼与埃克替尼先「卷」为敬, objectType=article, longId=804440, objectId=cc00804440fd, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20221109/1668021554762_4754896.jpeg, objectUrl=/article/show_article.do?id=cc00804440fd, replyNumber=0, likeNumber=41, createdTime=2023-12-11, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=cc00804440fd, moduleTitle=贝家讲坛 | 聚焦脑转移与共突变人群，原研EGFR-TKI贝福替尼与埃克替尼先「卷」为敬, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cc00804440fd)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1455550, encodeId=57d51455550e5, content=<a href='/topic/show?id=011941548ad' target=_blank style='color:#2F92EE;'>#埃克替尼#</a>, objectTitle=Transl Lung Cancer Res: 广医一院团队：第一代EGFR-TKIs(吉非替尼、厄洛替尼和埃克替尼)术后辅助治疗NSCLC伴有EGFR敏感突变患者的疗效比较, objectType=article, longId=295260, objectId=94052952604f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=94052952604f, replyNumber=0, likeNumber=42, createdTime=2022-02-09, rootId=0, userName=zhzhxiang, userId=c0275676034, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=94052952604f, moduleTitle=Transl Lung Cancer Res: 广医一院团队：第一代EGFR-TKIs(吉非替尼、厄洛替尼和埃克替尼)术后辅助治疗NSCLC伴有EGFR敏感突变患者的疗效比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=94052952604f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1455549, encodeId=54d814555496b, content=<a href='/topic/show?id=011941548ad' target=_blank style='color:#2F92EE;'>#埃克替尼#</a>, objectTitle=埃克替尼与安罗替尼治疗晚期非小细胞肺癌疗效比较及对miR-185-5p、miR-204-5p表达水平影响观察, objectType=article, longId=220671, objectId=e6e52206e1f8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e6e52206e1f8, replyNumber=0, likeNumber=33, createdTime=2021-11-22, rootId=0, userName=zhzhxiang, userId=c0275676034, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e6e52206e1f8, moduleTitle=埃克替尼与安罗替尼治疗晚期非小细胞肺癌疗效比较及对miR-185-5p、miR-204-5p表达水平影响观察, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e6e52206e1f8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1455548, encodeId=0c2d14555485c, content=<a href='/topic/show?id=011941548ad' target=_blank style='color:#2F92EE;'>#埃克替尼#</a>, objectTitle=Lancet Respir Med：周彩存教授团队发表埃克替尼术后辅助靶向研究数据（EVIDENCE研究）, objectType=article, longId=214475, objectId=5bd72144e5cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5bd72144e5cc, replyNumber=0, likeNumber=50, createdTime=2021-07-21, rootId=0, userName=zhzhxiang, userId=c0275676034, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5bd72144e5cc, moduleTitle=Lancet Respir Med：周彩存教授团队发表埃克替尼术后辅助靶向研究数据（EVIDENCE研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5bd72144e5cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1455547, encodeId=7b07145554e1f, content=<a href='/topic/show?id=011941548ad' target=_blank style='color:#2F92EE;'>#埃克替尼#</a>, objectTitle=Lancet respirat：同济大学3期临床试验揭示埃克替尼在EGFR突变型晚期NSCLC中的疗效, objectType=article, longId=214456, objectId=4803214456af, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4803214456af, replyNumber=0, likeNumber=37, createdTime=2021-07-21, rootId=0, userName=zhzhxiang, userId=c0275676034, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4803214456af, moduleTitle=Lancet respirat：同济大学3期临床试验揭示埃克替尼在EGFR突变型晚期NSCLC中的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4803214456af)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1455546, encodeId=0217145554626, content=<a href='/topic/show?id=011941548ad' target=_blank style='color:#2F92EE;'>#埃克替尼#</a>, objectTitle=贝达药业埃克替尼第3项适应症申报上市，用于NSCLC患者术后辅助治疗, objectType=article, longId=201089, objectId=b23f201089dc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b23f201089dc, replyNumber=0, likeNumber=0, createdTime=2020-09-24, rootId=0, userName=zhzhxiang, userId=c0275676034, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b23f201089dc, moduleTitle=贝达药业埃克替尼第3项适应症申报上市，用于NSCLC患者术后辅助治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b23f201089dc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1455545, encodeId=81d414555454d, content=<a href='/topic/show?id=011941548ad' target=_blank style='color:#2F92EE;'>#埃克替尼#</a>, objectTitle=肿瘤大咖有话说，何建行教授、胡坚教授、冯继锋教授和李印教授点评埃克替尼上市6周年, objectType=article, longId=119834, objectId=fa001198348b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fa001198348b, replyNumber=0, likeNumber=33, createdTime=2017-11-15, rootId=0, userName=zhzhxiang, userId=c0275676034, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fa001198348b, moduleTitle=肿瘤大咖有话说，何建行教授、胡坚教授、冯继锋教授和李印教授点评埃克替尼上市6周年, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fa001198348b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1455544, encodeId=c7cf145554465, content=<a href='/topic/show?id=011941548ad' target=_blank style='color:#2F92EE;'>#埃克替尼#</a>, objectTitle=Lancet Respir Med:NSCLC合并多处脑转移：埃克替尼vs全脑放疗, objectType=article, longId=116508, objectId=5d67116508b3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5d67116508b3, replyNumber=0, likeNumber=38, createdTime=2017-10-19, rootId=0, userName=zhzhxiang, userId=c0275676034, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5d67116508b3, moduleTitle=Lancet Respir Med:NSCLC合并多处脑转移：埃克替尼vs全脑放疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5d67116508b3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1455543, encodeId=7f861455543f8, content=<a href='/topic/show?id=011941548ad' target=_blank style='color:#2F92EE;'>#埃克替尼#</a>, objectTitle= LANCET RESPIR MED :埃克替尼对比全脑照射治疗EGFR突变的非小细胞肺癌合并多发脑肿瘤患者（BRAIN）疗效如何？, objectType=article, longId=107158, objectId=cb6710e1581d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cb6710e1581d, replyNumber=0, likeNumber=43, createdTime=2017-08-01, rootId=0, userName=zhzhxiang, userId=c0275676034, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cb6710e1581d, moduleTitle= LANCET RESPIR MED :埃克替尼对比全脑照射治疗EGFR突变的非小细胞肺癌合并多发脑肿瘤患者（BRAIN）疗效如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cb6710e1581d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1455542, encodeId=42c6145554218, content=<a href='/topic/show?id=011941548ad' target=_blank style='color:#2F92EE;'>#埃克替尼#</a>, objectTitle=Lancet Respir Med：国产新药埃克替尼可有效抑制脑肿瘤进展, objectType=article, longId=106072, objectId=76411060e2a8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=76411060e2a8, replyNumber=0, likeNumber=42, createdTime=2017-07-21, rootId=0, userName=zhzhxiang, userId=c0275676034, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=76411060e2a8, moduleTitle=Lancet Respir Med：国产新药埃克替尼可有效抑制脑肿瘤进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=76411060e2a8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1455541, encodeId=4dbb1455541b4, content=<a href='/topic/show?id=011941548ad' target=_blank style='color:#2F92EE;'>#埃克替尼#</a>, objectTitle=ASCO 2016：中国自主创新小分子靶向药物埃克替尼——CONVINCE研究结果揭晓, objectType=article, longId=70154, objectId=f312e015453, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f312e015453, replyNumber=0, likeNumber=44, createdTime=2016-06-08, rootId=0, userName=zhzhxiang, userId=c0275676034, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f312e015453, moduleTitle=ASCO 2016：中国自主创新小分子靶向药物埃克替尼——CONVINCE研究结果揭晓, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f312e015453)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1455540, encodeId=d3ff1455540a7, content=<a href='/topic/show?id=011941548ad' target=_blank style='color:#2F92EE;'>#埃克替尼#</a>, objectTitle=中国共识：埃克替尼治疗非小细胞肺癌（2015版）, objectType=article, longId=55198, objectId=fad5551981b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fad5551981b, replyNumber=0, likeNumber=41, createdTime=2015-08-23, rootId=0, userName=zhzhxiang, userId=c0275676034, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fad5551981b, moduleTitle=中国共识：埃克替尼治疗非小细胞肺癌（2015版）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fad5551981b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1455539, encodeId=fad3145553935, content=<a href='/topic/show?id=011941548ad' target=_blank style='color:#2F92EE;'>#埃克替尼#</a>, objectTitle=ASCO 2014：埃克替尼+全脑放疗脑转移的EGFR突变NSCLC患者的I期试验, objectType=article, longId=35668, objectId=21d935668a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=21d935668a7, replyNumber=0, likeNumber=47, createdTime=2014-06-02, rootId=0, userName=zhzhxiang, userId=c0275676034, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=21d935668a7, moduleTitle=ASCO 2014：埃克替尼+全脑放疗脑转移的EGFR突变NSCLC患者的I期试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=21d935668a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1455538, encodeId=1b9f1455538f2, content=<a href='/topic/show?id=011941548ad' target=_blank style='color:#2F92EE;'>#埃克替尼#</a>, objectTitle=CPP：研究示食物摄入显著增加埃克替尼的吸收和暴露水平, objectType=article, longId=34273, objectId=b6d3342e325, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b6d3342e325, replyNumber=0, likeNumber=35, createdTime=2014-05-07, rootId=0, userName=zhzhxiang, userId=c0275676034, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b6d3342e325, moduleTitle=CPP：研究示食物摄入显著增加埃克替尼的吸收和暴露水平, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b6d3342e325)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1455537, encodeId=4f0c145553e9c, content=<a href='/topic/show?id=011941548ad' target=_blank style='color:#2F92EE;'>#埃克替尼#</a>, objectTitle=Lancet Oncol：盐酸埃克替尼治疗晚期非小细胞肺癌有效, objectType=article, longId=24207, objectId=b8642420e35, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b8642420e35, replyNumber=0, likeNumber=39, createdTime=2013-09-13, rootId=0, userName=zhzhxiang, userId=c0275676034, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b8642420e35, moduleTitle=Lancet Oncol：盐酸埃克替尼治疗晚期非小细胞肺癌有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b8642420e35)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1455536, encodeId=ca6f145553639, content=<a href='/topic/show?id=011941548ad' target=_blank style='color:#2F92EE;'>#埃克替尼#</a>, objectTitle=ASCO 2013：上海胸科医院顾爱琴等证实埃克替尼对晚期非小细胞肺癌患者治疗安全有效, objectType=article, longId=19048, objectId=f8d41904884, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f8d41904884, replyNumber=0, likeNumber=48, createdTime=2013-05-23, rootId=0, userName=zhzhxiang, userId=c0275676034, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f8d41904884, moduleTitle=ASCO 2013：上海胸科医院顾爱琴等证实埃克替尼对晚期非小细胞肺癌患者治疗安全有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f8d41904884)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1455535, encodeId=6318145553569, content=<a href='/topic/show?id=011941548ad' target=_blank style='color:#2F92EE;'>#埃克替尼#</a>, objectTitle=ASCO 2011: 埃克替尼耐受性优于吉非替尼, objectType=article, longId=2728, objectId=72a62e2804, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=72a62e2804, replyNumber=0, likeNumber=0, createdTime=2011-06-22, rootId=0, userName=zhzhxiang, userId=c0275676034, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=72a62e2804, moduleTitle=ASCO 2011: 埃克替尼耐受性优于吉非替尼, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=72a62e2804)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1455534, encodeId=53ae14555348e, content=<a href='/topic/show?id=011941548ad' target=_blank style='color:#2F92EE;'>#埃克替尼#</a>, objectTitle=随机、双盲双模拟、平行对照、多中心评价埃克替尼和吉非替尼治疗既往接受过一个或两个化疗的局部晚期或转移的非小细胞肺癌患者的疗效和安全性III 期临床研究, objectType=article, longId=2151, objectId=08172151bb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=08172151bb, replyNumber=0, likeNumber=38, createdTime=2010-09-21, rootId=0, userName=zhzhxiang, userId=c0275676034, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=08172151bb, moduleTitle=随机、双盲双模拟、平行对照、多中心评价埃克替尼和吉非替尼治疗既往接受过一个或两个化疗的局部晚期或转移的非小细胞肺癌患者的疗效和安全性III 期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=08172151bb)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

埃克替尼

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#非小细胞肺癌# #EGFR# #埃克替尼# #贝福替尼#

贝家讲坛 | 聚焦脑转移与共突变人群，原研EGFR-TKI贝福替尼与埃克替尼先「卷」为敬

2023-12-11发表于上海

zhzhxiang (审核中...)

前往app查看评论内容

#埃克替尼#

Transl Lung Cancer Res: 广医一院团队：第一代EGFR-TKIs(吉非替尼、厄洛替尼和埃克替尼)术后辅助治疗NSCLC伴有EGFR敏感突变患者的疗效比较

2022-02-09

zhzhxiang (审核中...)

前往app查看评论内容

#埃克替尼#

埃克替尼与安罗替尼治疗晚期非小细胞肺癌疗效比较及对miR-185-5p、miR-204-5p表达水平影响观察

2021-11-22

zhzhxiang (审核中...)

前往app查看评论内容

#埃克替尼#

Lancet Respir Med：周彩存教授团队发表埃克替尼术后辅助靶向研究数据（EVIDENCE研究）

2021-07-21

zhzhxiang (审核中...)

前往app查看评论内容

#埃克替尼#

Lancet respirat：同济大学3期临床试验揭示埃克替尼在EGFR突变型晚期NSCLC中的疗效

2021-07-21

zhzhxiang (审核中...)

前往app查看评论内容

#埃克替尼#

贝达药业埃克替尼第3项适应症申报上市，用于NSCLC患者术后辅助治疗

2020-09-24

zhzhxiang (审核中...)

前往app查看评论内容

#埃克替尼#

肿瘤大咖有话说，何建行教授、胡坚教授、冯继锋教授和李印教授点评埃克替尼上市6周年

2017-11-15

zhzhxiang (审核中...)

前往app查看评论内容

#埃克替尼#

Lancet Respir Med:NSCLC合并多处脑转移：埃克替尼vs全脑放疗

2017-10-19

zhzhxiang (审核中...)

前往app查看评论内容

#埃克替尼#

LANCET RESPIR MED :埃克替尼对比全脑照射治疗EGFR突变的非小细胞肺癌合并多发脑肿瘤患者（BRAIN）疗效如何？

2017-08-01

zhzhxiang (审核中...)

前往app查看评论内容

#埃克替尼#

Lancet Respir Med：国产新药埃克替尼可有效抑制脑肿瘤进展

2017-07-21

zhzhxiang (审核中...)

前往app查看评论内容

#埃克替尼#

ASCO 2016：中国自主创新小分子靶向药物埃克替尼——CONVINCE研究结果揭晓

2016-06-08

zhzhxiang (审核中...)

前往app查看评论内容

#埃克替尼#

中国共识：埃克替尼治疗非小细胞肺癌（2015版）

2015-08-23

zhzhxiang (审核中...)

前往app查看评论内容

#埃克替尼#

ASCO 2014：埃克替尼+全脑放疗脑转移的EGFR突变NSCLC患者的I期试验

2014-06-02

zhzhxiang (审核中...)

前往app查看评论内容

#埃克替尼#

CPP：研究示食物摄入显著增加埃克替尼的吸收和暴露水平

2014-05-07

zhzhxiang (审核中...)

前往app查看评论内容

#埃克替尼#

Lancet Oncol：盐酸埃克替尼治疗晚期非小细胞肺癌有效

2013-09-13

zhzhxiang (审核中...)

前往app查看评论内容

#埃克替尼#

ASCO 2013：上海胸科医院顾爱琴等证实埃克替尼对晚期非小细胞肺癌患者治疗安全有效

2013-05-23

zhzhxiang (审核中...)

前往app查看评论内容

#埃克替尼#

ASCO 2011: 埃克替尼耐受性优于吉非替尼

2011-06-22

zhzhxiang (审核中...)

前往app查看评论内容

#埃克替尼#

随机、双盲双模拟、平行对照、多中心评价埃克替尼和吉非替尼治疗既往接受过一个或两个化疗的局部晚期或转移的非小细胞肺癌患者的疗效和安全性III 期临床研究

2010-09-21

科室
- - 订阅+
  - 更多科室
工具
服务